Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Materials (33)
- Advanced Manufacturing (1)
- Biology and Environment (13)
- Clean Energy (25)
- Computational Engineering (1)
- Computer Science (2)
- Fusion and Fission (4)
- Isotopes (2)
- Materials for Computing (5)
- National Security (11)
- Neutron Science (18)
- Nuclear Science and Technology (3)
- Quantum information Science (1)
- Supercomputing (43)
News Topics
- (-) Biomedical (3)
- (-) Computer Science (8)
- (-) Grid (2)
- (-) High-Performance Computing (2)
- (-) ITER (1)
- (-) Physics (14)
- (-) Polymers (6)
- 3-D Printing/Advanced Manufacturing (13)
- Advanced Reactors (1)
- Artificial Intelligence (4)
- Bioenergy (8)
- Biology (4)
- Buildings (2)
- Chemical Sciences (20)
- Climate Change (5)
- Composites (3)
- Coronavirus (2)
- Critical Materials (8)
- Cybersecurity (3)
- Decarbonization (4)
- Energy Storage (19)
- Environment (7)
- Exascale Computing (1)
- Frontier (2)
- Fusion (2)
- Isotopes (5)
- Machine Learning (2)
- Materials (38)
- Materials Science (35)
- Microscopy (12)
- Molten Salt (2)
- Nanotechnology (21)
- National Security (3)
- Net Zero (1)
- Neutron Science (18)
- Nuclear Energy (2)
- Partnerships (8)
- Quantum Computing (1)
- Quantum Science (10)
- Renewable Energy (1)
- Security (1)
- Summit (1)
- Sustainable Energy (7)
- Transformational Challenge Reactor (1)
- Transportation (4)
Media Contacts
Three researchers from the Department of Energy’s Oak Ridge National Laboratory have been elected fellows of the American Physical Society (APS). Fellows of the APS are recognized for their exceptional contributions to the physics enterprise in outstanding resear...
Scientists at the Department of Energy’s Oak Ridge National Laboratory used neutrons, isotopes and simulations to “see” the atomic structure of a saturated solution and found evidence supporting one of two competing hypotheses about how ions come
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.